PEPCLUB.me

Metabolic HealthPerformance & EnergyWeight ManagementAnti-AgingMitochondrial HealthArticlePremium

MOTS-C

10mg Vial

6 August 2026Updated 29 August 2026

MOTS-C

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for MOTS-C.

Create free account Member login

Full range of benefits for MOTS-C

Supports mitochondrial signaling and metabolic homeostasis

May improve insulin sensitivity and glucose regulation

Activates AMPK, enhancing cellular energy sensing

Promotes fatty acid oxidation and reduced lipid storage

Supports mitochondrial function and biogenesis in cells

May limit diet‑induced weight gain in animal studies

May enhance exercise capacity and skeletal muscle function

Modulates inflammatory markers and oxidative stress

May improve metabolic flexibility between fuels

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(4)Compatible(3)Monitor(4)Avoid(4)

Use with professional oversight

Insulin

Enhanced insulin sensitivity from MOTS-C may increase hypoglycaemia risk, so blood glucose and insulin dosing should be closely monitored and adjusted as needed.

Sulfonylureas (e.g., glipizide, glyburide)

Because MOTS-C can improve glucose uptake, clinicians should monitor glycaemia for hypoglycaemia and consider dose reduction of sulfonylureas.

Statins (e.g., atorvastatin, simvastatin)

Given potential overlapping effects on mitochondrial function, monitor for myalgias, CK elevations and hepatic function when combining with MOTS-C.

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin)

Monitor volume status, renal function and ketone levels since combined metabolic effects may alter glycaemic control and rare DKA risk.

All interaction categories

Synergistic (4)

Metformin: Both agents activate AMPK and improve insulin sensitivity and metabolic flexibility, potentially producing additive benefits in glycaemic control and lipid oxidation.
GLP-1 receptor agonists (e.g., liraglutide, semaglutide): Complementary mechanisms on glucose regulation and weight loss can enhance overall metabolic outcomes when combined with MOTS-C.
NAD+ precursors (nicotinamide riboside / nicotinamide mononucleotide): Supporting mitochondrial NAD+ pools may augment MOTS-C–mediated improvements in mitochondrial function and bioenergetics.
Omega-3 fatty acids (EPA/DHA): Omega-3s promote mitochondrial biogenesis and fatty acid oxidation and may synergize with MOTS-C to improve lipid metabolism and inflammation.

Compatible (3)

ACE inhibitors / ARBs (e.g., lisinopril, losartan): No expected pharmacodynamic or pharmacokinetic interaction with MOTS-C and these agents are generally neutral when co-administered in metabolic patients.
Levothyroxine: Thyroid hormone replacement is typically neutral with MOTS-C, but standard TFT monitoring for thyroid dose adjustments remains appropriate.
Proton pump inhibitors (e.g., omeprazole): No specific interaction with MOTS-C is expected and routine co-administration does not require special precautions.

Monitor (4)

Insulin: Enhanced insulin sensitivity from MOTS-C may increase hypoglycaemia risk, so blood glucose and insulin dosing should be closely monitored and adjusted as needed.
Sulfonylureas (e.g., glipizide, glyburide): Because MOTS-C can improve glucose uptake, clinicians should monitor glycaemia for hypoglycaemia and consider dose reduction of sulfonylureas.
Statins (e.g., atorvastatin, simvastatin): Given potential overlapping effects on mitochondrial function, monitor for myalgias, CK elevations and hepatic function when combining with MOTS-C.
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): Monitor volume status, renal function and ketone levels since combined metabolic effects may alter glycaemic control and rare DKA risk.

Avoid (4)

Nucleoside reverse transcriptase inhibitors (NRTIs, e.g., zidovudine): NRTIs are associated with mitochondrial toxicity and should be used with caution due to the potential for additive mitochondrial dysfunction.
Linezolid and other mitochondrial‑affecting antibiotics: Agents known to impair mitochondrial protein synthesis may exacerbate mitochondrial adverse effects and warrant careful risk–benefit assessment.
Mitochondrial‑toxic chemotherapies (e.g., doxorubicin): Chemotherapeutic agents with known mitochondrial toxicity may increase risk of organ dysfunction when combined with agents that modulate mitochondrial biology.
High‑dose stimulants / sympathomimetics: Drugs that substantially increase metabolic demand or catecholaminergic stress should be evaluated cautiously because altered energy metabolism from MOTS-C could modify cardiovascular and metabolic responses.